Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This promotional content discusses Locerin as a hair growth supplement but reports no research findings; readers are encouraged to explore their own conclusions.

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.

This study identified 53 keratins in the yak genome, predicting diverse phosphorylation sites and subcellular localizations, and highlighted strong gene expression correlations during the yak hair follicle development cycle.

In this study, researchers found that overexpression of LncRNA RP11-818O24.3 in hair follicle stem cells promotes their proliferation, self-renewal, and differentiation while inhibiting apoptosis through the FGF2-mediated PI3K/AKT signaling pathway, suggesting potential therapeutic applications for hair loss treatment.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This report describes two scalp lichen simplex chronicus cases with hair loss and intense itching, noting unique dermoscopic and histopathological features.

This study found that RANKL signaling enhances CD8+ T cell-mediated anti-viral immunity during herpes simplex virus infection by preventing apoptosis of Langerhans cells, suggesting potential therapeutic applications.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

This study found that KSR1 is essential for v-Ha-ras-mediated skin tumor formation in mice but not for MT-driven mammary tumor genesis, suggesting its potential as a therapeutic target in Ras/MAPK signaling.

This study found that certain lncRNA gene polymorphisms in HOTAIR and MALAT1 are associated with increased susceptibility to systemic lupus erythematosus, potentially informing clinical applications.

This case report details two patients with Graham-Little-Piccardi-Lassueur syndrome who showed marked skin lesion improvement with corticosteroid treatment, though cicatricial scalp alopecia remained unresponsive.

In this case report, a rare instance of Graham–Little–Piccardi–Lassueur syndrome coexisting with linear lichen planus was identified in a 35-year-old male, highlighting the condition's rarity in males, with dermoscopy aiding diagnosis through distinctive scalp and trunk lesion features.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This study suggests that label-retaining cells in the hair follicle contribute to follicular renewal, indicating a specific role in the hair cycle by proliferating during the late telogen phase.

This study found that certain gene polymorphisms in keratin 27 and ELOVL4 are linked to improved cashmere fineness and production traits in Liaoning cashmere goats.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

In this study, researchers observed that the epidermal specializations on the tail scales of Lygodactylus lizards, including sensory organs and specific secretory glands, are fully restored with similar structure and distribution on regenerated tails.

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This study suggests that although data on JAK inhibitors for treating LPP and FFA is mainly from retrospective studies and case reports, these inhibitors may offer a new treatment option, particularly for challenging cases.

This study concluded that the receptor-like kinase ERULUS, regulated by auxin, is crucial for modulating cell wall composition and pectin dynamics during root hair growth in Arabidopsis.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

This review highlights the potential roles of long non-coding RNAs (lncRNAs) in malignant brain tumors, reporting that further research into their involvement in therapy resistance and cancer pathways could improve diagnosis and treatment outcomes.

In this case report, two women with chronic alopecia areata and acute alopecia universalis experienced sustained and near-complete hair regrowth after over a year of treatment with oral ruxolitinib, without significant side effects.

This study investigates the potential role of the corticotropin-releasing hormone system in the pathogenesis of lichen planus but does not report new clinical results, emphasizing the need for further exploration.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.